A randomised comparison of 'Casodex'® (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

European Urology

Volumn 33, Issue 5, 1998, Pages 447-456

  Tyrrell, C J ^a   Kaisary, A V ^a   Iversen, P ^a   Anderson, J B ^a   Baert, L ^a   Tammela, T ^a   Chamberlain, M ^a   Webster, A ^a   Blackedge, G ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

'Casodex' ; Anti androgen; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BACKACHE; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EDEMA; FOLLOW UP; GYNECOMASTIA; HOT FLUSH; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MASTALGIA; METASTASIS; MULTICENTER STUDY; PAIN; PELVIS PAIN SYNDROME; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SWEATING; URINE RETENTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; BONE NEOPLASMS; CASTRATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031798627     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000019634     Document Type: Article

References (21)